ArticleDiabetes, obesity & metabolism2026
Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Projecting the Long-Term Cost-Effectiveness of Once-Weekly Insulin Icodec Versus Once-Daily Basal Insulin Analogs in Italy Using the Prime T2D Model.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIcodec is the first once-weekly basal insulin for type 2 diabetes (T2D), potentially improving quality of life through a reduced administration burden versus once-daily basal insulins. This study assessed the long-term cost-effectiveness of icodec versus glargine U100, degludec and a mix of once-daily basal insulins (degludec, glargine U100 and glargine U300) in insulin-naïve adults with T2D in Italy.
methodsOutcomes were projected over patient lifetimes (up to 60 years) using the PRIME T2D Model, discounted annually at 3.0%. Baseline characteristics and treatment effects were taken from ONWARDS 1, 3 and 5. Modelled patients received basal insulins for 4 years, before intensifying with the addition of bolus insulin. Treatment effects applied in the first year of the analysis and a utility benefit relating to once-weekly versus once-daily injection were maintained until intensification. Costs were expressed in 2024 euros (EUR) from the perspective of the Italian National Health Service.
resultsIcodec was associated with improved quality-adjusted life expectancy of 0.16 quality-adjusted life years (QALYs) versus glargine U100 and degludec, and 0.26 QALYs versus the once-daily insulin mix. Benefits primarily resulted from the reduced injection frequency with icodec. Higher acquisition costs with icodec were partially offset by reduced use of consumables and modelled reductions in diabetes-related complications. Icodec was associated with incremental cost-effectiveness ratios of EUR 25 623, EUR 5438 and EUR 3940 per QALY gained versus glargine U100, degludec and the once-daily insulin mix, respectively.
conclusionsIcodec was projected to be cost-effective versus once-daily insulins for insulin-naïve people with T2D in Italy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.